Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.
It was shown for the first time that the endogenous cyclic dipeptide cycloprolylglycine (CPG) at concentrations of 10(-7) and 10(-3) M and piracetam at a concentration of 10(-3) M increased the content of brainderived neurotrophic factor (BDNF) in the culture of neuronal cells in normal state and under conditions of glutamate and 6-oxydopamine neurotoxicity. This may indicate the possible involvement of BDNF in the mechanism of action of neuropeptide CPG and piracetam.
Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, ul. Baltiiskaya 8, Moscow, 125315, Russia. tata-sosnovka@mail.ru.
T A
TA
Gudasheva
Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, ul. Baltiiskaya 8, Moscow, 125315, Russia.
K N
KN
Koliasnikova
Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, ul. Baltiiskaya 8, Moscow, 125315, Russia.
T A
TA
Antipova
Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, ul. Baltiiskaya 8, Moscow, 125315, Russia.
S B
SB
Seredenin
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D018698:Glutamic Acid / Q000633:toxicity; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D051379:Mice; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000378:metabolism; D010456:Peptides, Cyclic / Q000494:pharmacology*; D010889:Piracetam / Q000494:pharmacology*
D019208:Brain-Derived Neurotrophic Factor; D018696:Neuroprotective Agents; D010456:Peptides, Cyclic; D018698:Glutamic Acid; D016627:Oxidopamine; C062238:cyclo(prolylglycyl); D010889:Piracetam